Effect of ezetimibe on the prevalence of cholelithiasis

World Journal of Gastroenterology

Volumn 18, Issue 40, 2012, Pages 5789-5792

  Stein, Assaf ^a   Hermoni, Doron ^b   Elis, Avishay ^a   Konikoff, Fred M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

Author keywords

Bile; Cholesterol; Ezetimibe; Gallstones; Neiman Pick C1 like Receptor

Indexed keywords

ATORVASTATIN; EZETIMIBE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHOLELITHIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GALLSTONE; HUMAN; MALE; PREVALENCE; RETROSPECTIVE STUDY;

EID: 84873930594     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i40.5789     Document Type: Article

References (25)

1. Attili AF, Carulli N, Roda E, Barbara B, Capocaccia L, Menotti A, Okoliksanyi L, Ricci G, Capocaccia R, Festi D. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I. COL.) Am J Epidemiol 1995; 141: 158-165
2. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-1511
3. Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med 2008; 358: 2804-2811
4. Bar-Meir S. Gallstones: prevalence, diagnosis and treatment. Isr Med Assoc J 2001; 3: 111-113
5. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006; 368: 230-239
6. Hui DY, Labonté ED, Howles PN. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption. Am J Physiol Gastrointest Liver Physiol 2008; 294: G839-G843
7. Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy. J Hepatol 2008; 48 Suppl 1: S124-S135
8. Marschall HU, Einarsson C. Gallstone disease. J Intern Med 2007; 261: 529-542
9. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-1948
10. Davis HR, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1). Atheroscler Suppl 2008; 9: 77-81
11. Davis HR, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA, Graziano MP, Altmann SW. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004; 279: 33586-33592
12. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007; 117: 1968-1978
13. Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204
14. Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009; 302: 2001-2007
15. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346
16. Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 455-462
17. Black DD. Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion. Am J Physiol Gastrointest Liver Physiol 2007; 293: G519-G524
18. Mansbach CM, Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol 2007; 293: G645-G650
19. Darkes MJ, Poole RM, Goa KL. Ezetimibe. Am J Cardiovasc Drugs 2003; 3: 67-76; discussion 77-78
20. Jakulj L, Vissers MN, Groen AK, Hutten BA, Lutjohann D, Veltri EP, Kastelein JJ. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res 2010; 51: 755-762
21. Yamaoka-Tojo M, Tojo T, Kosugi R, Hatakeyama Y, Yoshida Y, Machida Y, Aoyama N, Masuda T, Izumi T. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis 2009; 8: 41
22. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008; 4: 267-278
23. Farnier M. Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin. Fundam Clin Pharmacol 2007; 21 Suppl 2: 27-28
24. Catapano AL. The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. Fundam Clin Pharmacol 2007; 21 Suppl 2: 21-26
25. Genest J. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Can J Cardiol 2006; 22: 863-868